Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.37 |
| ▸ | CTSL | P07711 | 7/20 | 0.37 |
| ▸ | CTSS | P25774 | 5/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256300 | 0.91 | CTSK (0.36) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL19088513 | 0.90 | REN (0.34) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL18256326 | 0.89 | KDM1A (0.33) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL29540912 | 0.89 | CTSK (0.36) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL18256506 | 0.89 | REN (0.32) | REN | |
| SCHEMBL18256470 | 0.88 | CTSK (0.39) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL19245087 | 0.87 | REN (0.32) | REN | |
| SCHEMBL18256455 | 0.87 | CTSK (0.40) | CTSKCTSLCTSSCTSBREN | |
| SCHEMBL24297688 | 0.87 | STAT3 (0.30) | — | |
| SCHEMBL18256549 | 0.87 | SYK (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | CTSK 111/4885CTSL 77/4885CTSS 156/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSK 185/4885CTSL 129/4885CTSS 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.